Skip to main content
Equibles
BMY logo

BMY · Bristol Myers Squibb Co · Metrics

Track BMY — free

Use BMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$63.43 +1.11 (+1.78%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$129.66B
Shares
2.04B
Volume · Nov 13 9.27M Avg daily vol (3M) 10.87M

BMY metrics

106 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$63.43
Market cap
$129.66B

Price action

23 metrics
Price change (1W)
+2.1%
Price change (30D)
+4.7%
Price change (3M)
-0.6%
Price change (6M)
+11.3%
Price change (YTD)
+17.6%
Price change (1Y)
+30.4%
Trailing year
Price change (5Y)
+6.7%
52-week high
$68.09
52-week low
$45.79
Change from 52-week high
-6.8%
Change from 52-week low
+38.5%
Annualized volatility
27.8%
Annualized volatility (3M)
28.3%
Implied volatility (30D)
28.7%
IV rank (1Y)
44.8
IV percentile (1Y)
51.4
Beta
0.2
RSI (14D)
55.8
Price vs SMA 50
+2.5%
Price vs SMA 200
+5.1%
Avg volume (3M)
10.87M
Relative volume
0.9
Average dollar volume
$679.20M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
2.04B

Valuation

12 metrics
P / E (TTM)
14.0
Trailing earnings · reciprocal yield 7.1%
PEG ratio
—
EV / revenue
3.2×
reciprocal yield 31.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.6×
reciprocal yield 38.6%
P / book
5.5
reciprocal yield 18.1%
FCF yield
7.2%
TTM · current market cap
Buyback yield
0.0%
P / FCF
14.0
reciprocal yield 7.2%
P / operating cash flow
12.2
reciprocal yield 8.2%
Earnings yield
7.1%

Historical valuation

8 metrics
P / E historical average (3Y)
14.9×
reciprocal yield 6.7%
P / E historical average (5Y)
18.9×
reciprocal yield 5.3%
EV / revenue historical average (3Y)
3.0×
reciprocal yield 32.9%
EV / revenue historical average (5Y)
3.3×
reciprocal yield 30.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
4.0%
Trailing 12 months
Payout ratio
55.4%
Shareholder yield
—
Dividend / share (TTM)
$2.52
Dividend growth YoY
+1.6%
Dividend growth streak
4
Last ex-dividend
2026-10-02

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
69.2%
Operating margin
—
Trailing 12 months
Net margin
18.5%
Gross profit (TTM)
$34.64B
Operating profit (TTM)
—
Net income (TTM)
$9.24B
Trailing 12 months
Diluted EPS (TTM)
$4.52
FCF margin
18.6%
Effective tax rate
18.4%

Per share

11 metrics
Revenue per diluted share (TTM)
$24.44
Gross profit per diluted share (TTM)
$16.93
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$4.51
Operating cash flow per diluted share (TTM)
$5.20
Free cash flow per diluted share (TTM)
$4.53
Capital expenditures per diluted share (TTM)
$0.67
R&D per diluted share (TTM)
$5.16
Stock compensation per diluted share (TTM)
$0.27
Book value per share
$14.83

Growth

11 metrics
Revenue growth YoY
+6.9%
Year over year
Net income growth YoY
-1.8%
Revenue (TTM)
$50.03B
Trailing 12 months
EPS growth YoY
-2.8%
Shares change YoY
+0.7%
Year over year · more shares
Revenue CAGR (3Y)
+1.4%
Revenue CAGR (5Y)
+2.5%
EPS CAGR (3Y)
+5.5%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+2.4%
FCF CAGR (5Y)
-0.7%

Quality

14 metrics
Return on equity
39.5%
Return on assets
10.4%
Debt / equity
1.8
Current ratio
1.6
EBITDA (TTM)
—
Free cash flow (TTM)
$9.29B
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$33.30B
Latest balance sheet
Cash & equivalents
$9.57B
Total assets
$88.77B
Total debt
$42.88B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$10.65B
Capital expenditures (TTM)
$1.37B
R&D (TTM)
$10.56B
SG&A (TTM)
$7.32B
Stock compensation (TTM)
$552.00M
R&D / revenue
21.1%
Stock compensation / revenue
1.1%

Ownership (13F)

9 metrics
13F filers
2,542
13F filer change QoQ
-12
Institutional ownership
84.2%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
13.1%
Private-fund adviser ownership
12.6%
Active holders' share change QoQ
+0.2%
Holder tenure
19.7
Price vs estimated holder cost
+6.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.6%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$677,826
Insider-sentiment score
35 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 14272 CUSIP 110122108 13F (30d) 2056 filings 1929 filers Visit website Investor relations